CDSCO Panel Approves AstraZeneca pharma's Protocol Amendment proposal to study Anifrolumab
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved the drug major AstraZeneca Pharma India's protocol amendment proposal to study anifrolumab.
This came after the firm presented protocol amendment version 3.0 dated 07. 3. 2024 protocol no. D3460C00002. The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis.
Anifrolumab is a monoclonal antibody that inhibits type 1 interferon receptors and is indicated for treating moderate to severe systemic lupus erythematosus. This binding inhibits type I IFN signaling, thereby blocking the biological activity of type I IFNs. Anifrolumab-final also induces the internalization of IFNAR1, thereby reducing the levels of cell surface IFNAR1 available for receptor assembly.
Systemic sclerosis, or scleroderma, is a rare connective tissue disorder with an unknown and complex pathogenesis. The pathophysiology of systemic sclerosis is intricate and not entirely understood. The disease is characterized by 3 main hallmarks: vascular insult, autoimmunity, and tissue fibrosis.
At the recent SEC meeting for analgesics and rheumatology held on June 12 and 13, 2024, the expert panel reviewed protocol amendment version 3.0 dated 07. 3. 2024 protocol no. D3460C00002.
After detailed deliberation, the committee recommended the approval of the protocol amendment as presented by the firm.
Also Read: Sun Pharma Laboratories Gets CDSCO Panel Nod To study Antidiabetic FDC Drug
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.